Italian Study on Fertility Preservation and Pregnancy in Young Women
with Breast Cancer The PREFER Registry Program
Led by IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy · Updated on 2026-04-30
1000
Participants Needed
23
Research Sites
261 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting the PREgnancy and FERtility PREFER study to improve care and understanding of fertility preservation and pregnancy issues in young women with breast cancer. This comprehensive program includes two parts one focusing on fertility preservation choices and outcomes, and the other on managing breast cancer diagnosed during pregnancy and the health of children born after cancer treatment exposure. The study collects data over a long time to better understand these important topics.
The PREFER study gathers information on fertility preservation strategies available in Italy, including patients preferences, the techniques used, and their success and safety. It also tracks breast cancer cases diagnosed during pregnancy or soon after, monitoring pregnancy management, child health after exposure to cancer treatments in the womb, and outcomes for survivors who become pregnant later. The program is carried out across multiple Italian centers under a research group.
Participants provide data through medical records and follow-up over many years. Researchers measure how many patients choose fertility preservation, the types of treatments given during pregnancy, pregnancy complications, survival rates, ovarian function recovery, number of eggs preserved, and pregnancies achieved after treatment. They also evaluate hormone changes during chemotherapy and the health of children born to affected mothers. The study continues for up to 15 years to gather long-term safety and outcome information.
CONDITIONS
Brief Title
PREgnancy and FERtility Registry
Research Team
L
Lucia Del Mastro, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Lead Sponsor
Clinical Research Technology S.r.l.
Collaborating Sponsor
Who Can Participate
Age: 18Years - 45Years
FEMALE
Eligibility Criteria
You may qualify if you...
Diagnosis of breast cancer
Age between 18 and 45 years (for fertility study part)
No prior radiation or chemotherapy for cancer before enrollment (for fertility study part)
No metastatic disease (for fertility study part)
Diagnosis of breast cancer during pregnancy, within 1 year after pregnancy, or pregnancy after prior breast cancer diagnosis and treatment (for pregnancy study part)
Provided informed consent
You will not qualify if you...
Unable to provide written informed consent
Stage IV disease at diagnosis (for fertility study part)
Serious psychiatric disorders
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Long-term Monitoring
Duration - Up to 15 years
Participants are observed over time to assess fertility preservation strategies, pregnancy outcomes, and health following breast cancer treatments.
Periodic visits depending on individual follow-up schedules
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Evaluating Universal Versus Point-of-Care Antiviral Treatment to Prevent Mother-to-Child Transmission of Hepatitis B in Pregnant Women
Comparing 18F-FDG and 68Ga-FAPI-46 PET Scans in Women With ER-positive Breast Cancer
Study of Darcilil with Hormone Therapy and Pyrrotinib for Treating Elderly Women with Advanced Triple-Positive Breast Cancer
A Phase 3 Open-label Study Comparing Patritumab Deruxtecan to Doctors Choice Treatments for Locally Advanced or Metastatic Hormone Receptor-positive, HER2-negative Breast Cancer
Study of Sacituzumab Tirumotecan with Pembrolizumab and Chemotherapy Versus Chemotherapy with Pembrolizumab for Early-Stage High-Risk Triple-Negative or HR-Low PositiveHER2-Negative Breast Cancer
Long-term Extension Study of Niraparib Treatment for Adults Who Completed a Previous GlaxoSmithKlineTESARO Niraparib Study and Are Benefiting from Continued Therapy
Study of Multi-mode Thermophysical Immunotherapy vs Conventional Radiofrequency Ablation for Treating Breast Cancer Liver Metastases in Women Aged 18 to 75
Observational Study of Kisqali Ribociclib with Aromatase Inhibitor for Adjuvant Treatment in HRHER2- Early Breast Cancer at High Risk of Recurrence to Assess Real-World Effectiveness, Safety, and Patient Experience
Phase I Open-Label Study Evaluating Imaging, Safety, and Pharmacokinetics of 68GaGa-DWJ155 in Adults with Advanced Breast and Non-Small Cell Lung Cancers
Prediction Model Study for Pregnancy Outcomes in Women Affected by Aplastic Anemia
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
The PREgnancy and FERtility (PREFER) study: an Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients.